Evidence map›Paper›PMID 40783459›Full record

ArticleDigestive diseases and sciences2026

Aspiration Risk During Endoscopic Procedures While on GLP-1 Agonist Therapy.

Maryana Stryelkina, Robert Molina, Thomas Janice, Anupama Ancha, Justin Bejcek, Fladie Ian, Michael Mullarkey, Christopher Johnson

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maryana StryelkinaDivision of Internal Medicine, Department of Medicine, Baylor Scott & White Medical Center, Temple, TX, 76508, USA.
Robert MolinaDivision of Internal Medicine, Department of Medicine, Baylor Scott & White Medical Center, Temple, TX, 76508, USA.
Thomas JaniceDivision of Internal Medicine, Department of Medicine, Baylor Scott & White Medical Center, Temple, TX, 76508, USA.
Anupama AnchaDivision of Gastroenterology, Department of Medicine, Baylor Scott & White Medical Center, 2401 S. 31st Street, Temple, TX, 76508, USA.
Justin BejcekDepartment of Medical Education, Edward Via College of Osteopathic Medicine, Monroe, LA, 71203, USA.
Fladie IanDivision of Internal Medicine, Department of Medicine, Baylor Scott & White Medical Center, Temple, TX, 76508, USA.
Michael MullarkeyDivision of Gastroenterology, Department of Medicine, Baylor Scott & White Medical Center, 2401 S. 31st Street, Temple, TX, 76508, USA.
Christopher JohnsonDivision of Gastroenterology, Department of Medicine, Baylor Scott & White Medical Center, 2401 S. 31st Street, Temple, TX, 76508, USA. Christopher.Johnson@BSWHealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGLP-1 receptor agonists (GLP-1RAs) are increasingly prescribed for Type 2 diabetes and weight management. Given their effect on gastric emptying, concerns have emerged regarding aspiration risk during endoscopic procedures. While aspiration risk is recognized during esophagogastroduodenoscopy (EGD), data on GLP-1RA users-particularly those undergoing colonoscopy-are limited. This study evaluated aspiration risk in patients undergoing EGD versus colonoscopy while on GLP-1RA therapy.

methodsWe performed a retrospective cohort study of adult patients (18-70 years) who underwent EGD or colonoscopy at Baylor Scott & White Medical Center Temple from July 2017 to July 2024. Patients were stratified by GLP-1RA use. The primary outcome was aspiration-related diagnosis within 30 days, identified via ICD-10 codes. Chi-square testing and logistic regression were used to assess associations.

resultsAmong 13,523 patients (7431 EGD; 6092 colonoscopy), 713 (5.3%) were GLP-1RA users. Aspiration events were more frequent following EGD than colonoscopy (adjusted OR = 2.36, P = 0.0200). No aspiration events occurred in GLP-1RA users. Multivariable analysis identified Black race as independently associated with increased aspiration risk (adjusted OR = 2.77, P = 0.0061), while higher BMI was associated with lower aspiration risk. GLP-1RA users had higher BMI and more frequent diabetes and gastroparesis, but no independent association with aspiration risk was observed.

conclusionAspiration risk was significantly higher with EGD than colonoscopy, but GLP-1RA use did not increase aspiration risk for either procedure. These findings suggest that routine GLP-1RA use may not be associated with increased aspiration risk in the outpatient setting. Prospective studies are needed to guide risk-based peri-procedural management.

Indexed as

ColonoscopyDiabetes Mellitus, Type 2Endoscopy, Digestive SystemGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsRespiratory AspirationAdolescentAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsYoung AdultGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsAspiration pneumoniaColonoscopyDelayed gastric emptyingEGDGLP-1 receptor agonists

Identifiers

PMID40783459

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.